Last reviewed · How we verify

bepotastine besilate ophthalmic solution

Bausch & Lomb Incorporated · FDA-approved active Small molecule Quality 40/100

Bepotastine blocks H1 receptors and inhibits histamine release from mast cells.

Bepotastine besilate ophthalmic solution, marketed by Bausch & Lomb, is an approved treatment for allergic conjunctivitis. Its dual mechanism of action, blocking H1 receptors and inhibiting histamine release from mast cells, provides a strong therapeutic profile. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic namebepotastine besilate ophthalmic solution
SponsorBausch & Lomb Incorporated
TargetH1-receptor, mast cells
ModalitySmall molecule
PhaseFDA-approved

Mechanism of action

Bepotastine works by directly blocking H1 receptors, which prevents the effects of histamine. Additionally, it stops mast cells from releasing histamine, reducing allergic symptoms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: